Skip to content
Biodatica
Start free

Investigator

Wei Li

TEXAS TECH UNIVERSITY · funded by NCI, NHLBI, NEI

Companies
3

Resolved onto their grants.

Grants
15

Federal awards on file.

Non-dilutive funding
$7.2M

Summed across those awards.

First award
Jan 1, 2011

Latest Jun 1, 2026.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R15

    Microfluidic Isolation and Deep Learning-based Profiling of Subtypes of Circulating Tumor Cells during Epithelial Mesenchymal Transition

    $607k

    Jun 1, 2026NCITEXAS TECH UNIVERSITYNIH RePORTER · 11361375 (opens the source filing in a new tab)

  2. R41

    Development of a potent and highly brain-penetrable antimitotic agent SEAK193 to treat breast cancer brain metastasis

    $400k

    Sep 19, 2025NCISEAK THERAPEUTICS, LLCNIH RePORTER · 11312503 (opens the source filing in a new tab)

  3. R01

    Targeted MDM2 degradation for improved treatment for triple-negative breast cancer

    $659k

    Aug 7, 2025NCIUNIVERSITY OF TENNESSEE HEALTH SCI CTRNIH RePORTER · 11234145 (opens the source filing in a new tab)

  4. R01

    Sodium Pump, Sex Hormones, and Thrombosis

    $498k

    Aug 1, 2025NHLBIMARSHALL UNIVERSITYNIH RePORTER · 11226819 (opens the source filing in a new tab)

  5. R01

    Sodium Pump, Sex Hormones, and Thrombosis

    $476k

    Aug 1, 2025NHLBIMARSHALL UNIVERSITYNIH RePORTER · 11378808 (opens the source filing in a new tab)

  6. R01

    The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential

    $568k

    Jul 1, 2025NEIBAYLOR COLLEGE OF MEDICINENIH RePORTER · 11102831 (opens the source filing in a new tab)

  7. R01

    The role of vascular ligands and neurovascular dysfunction in glaucoma and therapeutic potential

    $525k

    Jul 1, 2025NEIBAYLOR COLLEGE OF MEDICINENIH RePORTER · 11350897 (opens the source filing in a new tab)

  8. R01

    Paradoxical role of anti-VEGF therapy in subretinal fibrosis of wet AMD

    $670k

    Sep 1, 2024NEIBAYLOR COLLEGE OF MEDICINENIH RePORTER · 11171763 (opens the source filing in a new tab)

  9. R01

    Targeting brain and bone metastases in metastatic breast cancer for improved patient survival

    $615k

    Apr 20, 2023NCIUNIVERSITY OF TENNESSEE HEALTH SCI CTRNIH RePORTER · 11059072 (opens the source filing in a new tab)

  10. R01

    Targeting brain and bone metastases in metastatic breast cancer for improved patient survival

    $615k

    Apr 20, 2023NCIUNIVERSITY OF TENNESSEE HEALTH SCI CTRNIH RePORTER · 11312597 (opens the source filing in a new tab)

  11. R01

    The Pathophysiological Role of Cerebellar Glia in Rett Syndrome

    $89k

    Apr 1, 2021NINDSHENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCESNIH RePORTER · 11379153 (opens the source filing in a new tab)

  12. R01

    The Pathophysiological Role of Cerebellar Glia in Rett Syndrome

    $340k

    Apr 1, 2021NINDSHENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCESNIH RePORTER · 11251632 (opens the source filing in a new tab)

  13. R01

    The role and mechanism of necrosis in glioblastoma

    $354k

    Feb 1, 2021NINDSPENNSYLVANIA STATE UNIV HERSHEY MED CTRNIH RePORTER · 11019857 (opens the source filing in a new tab)

  14. R01

    Computational and Experimental Modeling of Alternative Polyadenylation

    $360k

    Dec 1, 2015NCIUNIVERSITY OF CALIFORNIA-IRVINENIH RePORTER · 11018594 (opens the source filing in a new tab)

  15. R01

    Targeting the colchicine binding site in tubulin for cancer therapy

    $390k

    Jan 1, 2011NCIUNIVERSITY OF TENNESSEE HEALTH SCI CTRNIH RePORTER · 11141738 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources